Jeffrey B. Landau - Dec 17, 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role: Chief Business Officer
Signature: /s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B Landau
Stock symbol: CTMX
Transactions as of: Dec 17, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/19/2023, 07:56 PM
Previous filing: Sep 22, 2023
Next filing: Dec 22, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTMX	Common Stock	Options Exercise	$0	+11.3K	+14.16%	$0.00	90.7K	Dec 17, 2023	Direct	F1, F2, F3
holding	CTMX	Common Stock						4.5K	Dec 17, 2023	Fidelity Traditional IRA
holding	CTMX	Common Stock						3.18K	Dec 17, 2023	Schwab ROTH IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTMX	Performance Stock Units (PSUs)	Options Exercise	$0	-11.3K	-50%	$0.00	11.3K	Dec 17, 2023	Common Stock	11.3K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
F2	Includes 52,205 restricted stock units.
F3	Includes 1,310 shares and 1,760 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2023 and November 30, 2023, respectively.
F4	Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.